Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.
Gå till den engelska sidan7-day roundup
The 10 most notable cure or vaccine studies from the last week.
Phase 3 trial testing a new 13-valent pneumococcal vaccine in healthy infants. Aims to prevent serious infections like pneumonia and meningitis.
Read lead report →Phase 3 trial testing a new mRNA COVID-19 vaccine (mRNA-1283) vs. an approved one in 13,553 people aged 12+ to prevent COVID-19.
Read report →A phase 2b study testing different schedules of the R21/Matrix-M malaria vaccine in African infants to find the best timing for protection.
Read report →This trial tests a new 24-valent pneumococcal vaccine for safety and immune response in people from 2 months old and up. Phase 1/2 study.
Read report →Phase 1 trial testing a custom-made dendritic cell vaccine for men with metastatic castration-resistant prostate cancer. Safety and immune response focus.
Read report →Study compares methods to boost HPV vaccine completion in underserved teens at community health centers. Results guide future vaccination efforts.
Read report →This phase 3 study tests a single dose of dTpa vaccine in healthy pregnant women to protect them and their newborns from diphtheria, tetanus, and pertussis.
Read report →This study tested a rabies vaccine given under the skin in adults. It checked safety and immune response after exposure risk.
Read report →This trial compared a 3rd dose of CoronaVac or Comirnaty in adults who had two doses of either vaccine at least 6 months earlier.
Read report →Phase 3 trial comparing adjuvanted vs standard flu vaccine immune response in healthcare workers in Peru. Key outcomes: antibody levels at 28 days and 6 months.
Read report →